A Phase 1/1b Open-Label, Dose-Escalation Study of Monoclonal Antibody AV-203 Administered as Monotherapy in Subjects with Metastatic or Advanced Solid Tumors or in Combination with Cetuximab (Erbitux) in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Trial Profile

A Phase 1/1b Open-Label, Dose-Escalation Study of Monoclonal Antibody AV-203 Administered as Monotherapy in Subjects with Metastatic or Advanced Solid Tumors or in Combination with Cetuximab (Erbitux) in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2015

At a glance

  • Drugs AV 203 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors AVEO Oncology
  • Most Recent Events

    • 07 Apr 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 02 Jul 2014 New source identified and integrated (M.D. Anderson Cancer Center record:2012-0268)
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top